Lazertinib is a product developed and produced by which pharmaceutical company

Lazertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI), mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR mutations. The drug was developed by the Korean pharmaceutical company Yuhan Corporation and will be launched in South Korea in 2021 under the trade name of Leclaza. Subsequently, Yoohan & Co. licensed its global development and commercialization license to Janssen Biotech, a subsidiary of Johnson & Johnson, which named it Lazcluze in the U.S. market.

Yoohan Yang & Co. was founded in 1941 and is headquartered in Seoul, South Korea. It is one of the leading pharmaceutical companies in South Korea. The company has profound accumulation in drug research and development, especially in the fields of anti-tumor drugs and antibiotics, and has made remarkable achievements. The research and development of lanzatinib began in 2015 and was initially developed by Genosco, a subsidiary of Yokoham & Co. 2015In July 2015, Genosco reached a cooperation agreement with Yoo Han Corporation to jointly develop Lanzertinib. In 2018, Yoo Han & Co. licensed the global development and commercialization license of the drug to Janssen Biotech, a subsidiary of Johnson & Johnson. This collaboration enables lanzatinib to conduct clinical trials and launch globally.

In20248 month, Johnson & Johnson'sJanssen Biotechannounced that the U.S.FDA approved lanzutinib (Lazcluze) and amivantamab (amivantamab-vmjw, trade nameRybrevant) combination for the treatment of patients with locally advanced or metastatic non-small cell lung cancer carrying EGFRexon19 deletion or exon21 L858R substitution mutation. This approval marks the official launch of lanzatinib in the U.S. market and provides patients with a new treatment option.

In short, lanzetinib was developed by South Korean pharmaceutical company Yuhan Yang, and achieved global clinical development and commercialization through cooperation with Janssen Biotech, a subsidiary of Johnson & Johnson. This collaboration not only promotes the global launch of Lanzitinib, but also provides patients with more treatment options.

Reference materials:https://www.drugs.com/donanemab.html